Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nordic Nanovector ASA ( (DE:8NN) ) has issued an announcement.
Thor Medical ASA has successfully completed a private placement and a retail offering, raising a total of NOK 86.4 million in gross proceeds. This capital increase has been registered with the Norwegian Register of Business Enterprises, resulting in a new share capital of NOK 69,797,184, divided into 348,985,920 shares. This financial maneuver is likely to strengthen Thor Medical’s operational capabilities and market positioning in the radiopharmaceutical industry.
More about Nordic Nanovector ASA
Thor Medical ASA is an emerging supplier in the radiopharmaceutical industry, specializing in the production of radionuclides, primarily alpha particle emitters derived from naturally occurring thorium. The company utilizes a proprietary production process that does not require irradiation or nuclear reactors, ensuring a reliable, environmentally friendly, and cost-efficient supply of alpha-emitters. Thor Medical is based in Oslo, Norway, and is publicly traded on the Oslo Stock Exchange under the ticker ‘TRMED’.
Average Trading Volume: 2,133,987
Current Market Cap: NOK778.2M
For detailed information about 8NN stock, go to TipRanks’ Stock Analysis page.